Prophylactic agent, onset-suppressing agent or therapeutic agent for progressive immune demyelinating diseases

Abstract

The present invention provides a prophylactic agent, onset-suppressing agent, or therapeutic agent for progressive immune demyelinating diseases comprising, as an active ingredient, a substance capable of suppressing or inhibiting production of prolactin.

1 . A prophylactic agent, onset-suppressing agent, or therapeutic agent for progressive immune demyelinating diseases comprising, as an active ingredient, a substance capable of suppressing or inhibiting production of prolactin. 
     
     
         2 . The prophylactic agent, onset-suppressing agent, or therapeutic agent for progressive immune demyelinating diseases according to  claim 1 , wherein the substance comprises a substance capable of suppressing or inhibiting generation of Zbtb20. 
     
     
         3 . The prophylactic agent, onset-suppressing agent, or therapeutic agent for progressive immune demyelinating diseases according to  claim 1 , wherein the substance comprises a dopamine receptor agonist or a dopamine receptor partial agonist. 
     
     
         4 . The prophylactic agent, onset-suppressing agent, or therapeutic agent for progressive immune demyelinating diseases according to  claim 1 , wherein the progressive immune demyelinating disease is secondary progressive multiple sclerosis. 
     
     
         5 . A method for preventing or suppressing a progression into progressive immune demyelinating diseases, comprising administering, to a subject, a substance capable of suppressing or inhibiting production of prolactin. 
     
     
         6 . The method according to  claim 5 , wherein the substance comprises a substance capable of suppressing or inhibiting generation of Zbtb20. 
     
     
         7 . The method according to  claim 5 , wherein the substance comprises a dopamine receptor agonist or a dopamine receptor partial agonist. 
     
     
         8 . The method according to  claim 5 , wherein the progressive immune demyelinating disease is secondary progressive multiple sclerosis. 
     
     
         9 . (canceled) 
     
     
         10 . (canceled) 
     
     
         11 . (canceled) 
     
     
         12 . (canceled) 
     
     
         13 . A prophylactic agent, onset-suppressing agent, or therapeutic agent for progressive immune demyelinating diseases comprising, as an active ingredient, a substance capable of suppressing or inhibiting activation of CX3CR1 receptor. 
     
     
         14 . The prophylactic agent, onset-suppressing agent, or therapeutic agent for progressive immune demyelinating diseases according to  claim 13 , wherein the substance is an anti-CX3CR1 antibody or an antigen-binding fragment thereof. 
     
     
         15 . A method of collecting data for diagnosing a progression into progressive immune demyelinating diseases comprising: collecting microglia from a human subject; and measuring an expression level of at least one of IL-9, IFN-α, and IFN-β1. 
     
     
         16 . The prophylactic agent, onset-suppressing agent, or therapeutic agent for progressive immune demyelinating diseases according to  claim 2 , wherein the progressive immune demyelinating disease is secondary progressive multiple sclerosis. 
     
     
         17 . The prophylactic agent, onset-suppressing agent, or therapeutic agent for progressive immune demyelinating diseases according to  claim 3 , wherein the progressive immune demyelinating disease is secondary progressive multiple sclerosis. 
     
     
         18 . The method according to  claim 6 , wherein the progressive immune demyelinating disease is secondary progressive multiple sclerosis. 
     
     
         19 . The method according to  claim 7 , wherein the progressive immune demyelinating disease is secondary progressive multiple sclerosis.